Executive Summary

- As of 17 May 2021, 162,773,940 confirmed cumulative cases of COVID-19 have been reported globally, including 3,375,573 deaths, for which the Region of the Americas contributed 40% of cases and 47% of deaths.

- In April 2021, the South America subregion accounted for the highest proportion of cases and deaths in the Region of the Americas. Compared to March 2021, an additional 809,233 cases and 45,410 deaths were reported.

- As of 17 May 2021, Argentina, Aruba, Canada, Mexico, Panama, and the United States of America have detected the four variants of concern (VOC).

- Compared to data reported in 2020, an increase in both the number of cases and deaths among pregnant women positive to SARS-CoV-2 has been observed from January through April 2021, in at least 12 countries of the Americas. If the increasing trend continues, the number of cases and deaths reported this year will soon exceed the numbers reported for all of 2020.

- Among indigenous peoples in 18 countries of the Americas, 448,956 cases were reported, including 7,884 deaths.

- A total of 22 countries and territories have reported 5,555 cumulative confirmed cases of multisystem inflammatory syndrome in children and adolescents (MIS-C) temporally related to COVID-19, including 123 deaths.

- Regarding health workers, 23 countries have reported 1,827,427 cases, including 9,161 deaths.
Table of Contents

Context................................................................................................................................. - 2 -
Global Situation Summary..................................................................................................... - 3 -
Situation Summary in the Region of the Americas ............................................................... - 4 -
Epidemiological Highlights.................................................................................................... - 7 -
  I. SARS-CoV-2 Variants ......................................................................................................... - 7 -
  II. COVID-19 among older adults (≥60 years of age).......................................................... - 11 -
  III. COVID-19 during pregnancy ........................................................................................ - 12 -
  IV. COVID-19 among indigenous populations ..................................................................... - 14 -
  V. COVID-19 among populations under 20 years of age.................................................... - 16 -
     Multisystem inflammatory syndrome in children and adolescents (MIS-C)................. - 18 -
  VI. COVID-19 among health workers ................................................................................ - 21 -
Guidance for national authorities........................................................................................ - 22 -
References .............................................................................................................................. - 23 -

Context

On 31 December 2019, the People’s Republic of China notified a cluster of pneumonia cases with unknown etiology, later identified on 9 January 2020 as a novel coronavirus by the Chinese Center for Disease Control and Prevention. On 30 January 2020, the World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern (PHEIC). On 11 February 2020, WHO named the disease “coronavirus disease 2019 (COVID-19),” and the International Committee on Taxonomy of Viruses (ICTV) named the virus “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).” On 11 March 2020, COVID-19 was declared a pandemic by the WHO Director-General, and on 31 July 2020, the WHO Director-General accepted the advice of the Emergency Committee, declaring that the COVID-19 pandemic continues to constitute a PHEIC, and issuing the temporary recommendations to States Parties under the International Health Regulations (IHR) (2005). On 9 July 2020, the WHO Director-General announced the launch of the Independent Panel for Pandemic Preparedness and Response (IPPR), which will independently and comprehensively assess the lessons learned from the international health response to COVID-19.

The seventh meeting of the Emergency Committee convened by the WHO Director-General under the International Health Regulations (2005) (IHR) regarding COVID-19 was held on Thursday, 15 April 2021. The Director-General determined that the COVID-19 pandemic continues to constitute a public health emergency of international concern and accepted the advice of the Committee to WHO and issued the Committee’s advice to States Parties as Temporary Recommendations under the IHR, available at: https://bit.ly/3eO4yXP.

---

Global Situation Summary

Since the first confirmed cases of COVID-19 until 17 May 2021, a cumulative total of 162,773,940 confirmed cases of COVID-19 have been reported globally, including 3,375,573 deaths, representing a total of 26,658,506 additional confirmed cases and 438,657 additional deaths since the last PAHO/WHO Epidemiological Update on COVID-19 published on 14 April 2021.

At the global level, since the first confirmed cases were reported, the highest number of new cases was reported the week of 19 April 2021 with 5,743,532 cases. Regarding deaths, the highest number was reported during the week of 18 January 2021, with 99,165 deaths.

When observing the epidemic curve of cases at the global level, we can note that, except for the period between 18 January and 29 March 2021, the number of weekly cases in 2021 has exceeded the weekly totals reported in 2020. Related to deaths, since the beginning of January 2021, except between 15 February and 5 April, the number of weekly deaths has consistently surpassed the peak observed at the end of 2020. (Figure 1)

Figure 1. Distribution of global COVID-19 confirmed cases and deaths, by week. January 2020 to 17 May 2021.


---

Figure 2. Distribution of confirmed COVID-19 cases and deaths, by subregion and month of report. Region of the Americas, March 2020 to April 2021.

Source: Information shared by IHR National Focal Points (NFPs) or published on the websites of the Ministries of Health, Health Agencies or similar and reproduced by PAHO/WHO.

The following is a brief analysis of the epidemiological situation of COVID-19 in Cuba. Additional details of the epidemiological situation in Cuba will be further presented in some sections of this Epidemiological Update.

* It should be noted that the analysis is carried out with the available data, which could have limitations, such as delay in the notification or in the loading of the data in the different systems; the differences in days between when the case starts symptoms, consults and the examination is requested, which influences the trend of the epidemic curves; in asymptomatic cases, the time difference between the collection of the sample and the result of the examination is delivered and the information loaded into the registry system. The different methodologies at the local level for contact traceability, which influences the ability to capture new cases, among other factors.
The first cases of COVID-19 in Cuba was confirmed on 11 March 2020. Since then and until 11 May 2021, there have been 119,375 cumulative confirmed cases, including 768 deaths, with a cumulative incidence rate of 135.6 per 100,000 population and a case-fatality rate of 0.64%.

For the analysis of COVID-19 cases and deaths in Cuba in this Update, the data published on the COVID19CubaData website were used\(^{10}\), and population data were obtained from the population projections published by the United Nations Populations Division\(^{11}\).

In order to determine whether the observed changes in temporal trends by epidemiological week (EW) were statistically significant, incidence rates per 100,000 population were analyzed using Joinpoint software\(^{12}\). The results are described below.

When modeling the weekly incidence rate, 6 changes in the trend were identified, of which 4 were statistically significant: the first, between EW 12 and EW 16 of 2020, with a weekly percentage change (WPC) of 30.59%; the second, between EW 16 and EW 30 of 2020 with a WPC of -7.77%; the third, between EW 30 and EW 34 of 2020 with a WPC of 43.82%, and the fourth between EW 40 of 2020 and EW 5 of 2021 with a WPC of 33.63%. The other two changes, which were not statistically significant, occurred between EW 34 and EW 48 of 2020, with a WPC of -1.97% and between EW 5 and EW 18 of 2021, with a WPC of 3.07% \(^{\text{Table 1}}\).

**Table 1. Weekly Percent Change in Modeled COVID-19 Incidence Rates. Cuba, EW 12 of 2020 to EW 18 of 2021.**

<table>
<thead>
<tr>
<th>EW</th>
<th>WPC</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 - 16, 2020</td>
<td>30.59*</td>
</tr>
<tr>
<td>16 - 30,2020</td>
<td>-7.77*</td>
</tr>
<tr>
<td>30 - 34,2020</td>
<td>43.82*</td>
</tr>
<tr>
<td>34 - 38, 2020</td>
<td>-1.97</td>
</tr>
<tr>
<td>48, 2020 - 5,2021</td>
<td>33.63*</td>
</tr>
<tr>
<td>5 - 18,2021</td>
<td>3.07</td>
</tr>
</tbody>
</table>

\(^{\ast}\)Statistically significant

**Source:** Data published by COVID19CubaData and analyzed by PAHO/WHO.

For the analysis of the mortality rate, R software\(^{13}\) was used. The analysis demonstrates three peaks in mortality rates, two of which occurred in 2020 and the third, of greater magnitude than the previous ones is currently in progress and began in EW 1 of 2021, with a statistically significant weekly increase of 11% (95% CI: 7.5% - 15.3%) between EW 2 and EW 18 of 2021 \(^{\text{Figure 3}}\).
**Figure 3.** Modeled mortality rate for COVID-19 by epidemiological week (EW). Cuba. EW 12 of 2020 and EW 18 of 2021.

*Per 100,000 population

**Source:** Data published by COVID19CubaData and analyzed by PAHO/WHO.

The use of programs such as Joinpoint or similar to model trend curves is important for monitoring when changes are occurring or have occurred, taking into account the implemented measures that could have had an influence on those changes. The analysis of these factors corresponds to the national authorities.

**Epidemiological Highlights**

**I. SARS-CoV-2 Variants**

The appearance of mutations is a natural and expected event within the evolutionary process of viruses. Since the initial genomic characterization of SARS-CoV-2, this virus has been divided into different genetic groups or clades. In fact, some specific mutations define the viral genetic groups (also called lineages) that are currently circulating globally. Due to various microevolution processes and selection pressures, some additional mutations may appear, generating differences within each genetic group (called variants). It is important to mention that the names of the clade, lineage, variant, etc., are arbitrary and do not correspond to an official taxonomic hierarchy.

Since the initial identification of SARS-CoV-2 until 17 May 2021, more than 1,578,988 complete genomic sequences have been shared globally through publicly accessible databases.

As of 17 May 2021, 43 countries and territories in the Americas have published a total of 505,008 SARS-CoV-2 genomes on the GISAID platform, collected between February 2020 and May 2021. The countries and territories that have contributed genome data are: Antigua and Barbuda, Argentina, Aruba, Bahamas, Barbados, Belize, Bermuda, Bolivia, Bonaire, Brazil, the British Virgin Islands, Canada, the Cayman Islands, Chile, Colombia, Costa Rica, Cuba, Curaçao, the Dominican Republic, Ecuador, El Salvador, Guadeloupe, Guatemala, French Guiana, Jamaica, Martinique, Mexico, Panama, Paraguay, Peru, Puerto Rico, Saint Barthelemy, Saint Kitts and Nevis, Saint Lucia, Saint Martin, Saint Vincent and the Grenadines, Sint Eustatius, Suriname, Trinidad and Tobago, the United States of America, Uruguay, and Venezuela.
On 25 February 2021, WHO provided proposed operational definitions for SARS-CoV-2 variants of interest (VOI) and variants of concern (VOC) and the associated actions that WHO will take to support Member States and their national public health institutes and reference laboratories, along with recommended actions that should be taken by Member States. The document includes general and non-exhaustive guidance on the prioritization of variants of greatest public health relevance in the broader context of SARS-CoV-2 transmission, and public health response mechanisms and established social distance measures. These definitions will periodically be reviewed and updated, as necessary. The full publication is available at: https://bit.ly/3wjt8Gd

On 11 May 2021, WHO classified an additional SARS-CoV-2 variant, B.1.617 lineage\(^\text{14}\), which was first detected in India, as a VOC, bringing the number of VOC to 4 and maintaining the previous list of six VOI.

The list of SARS-CoV-2 variants, according to the WHO classification as of 11 May 2021, is available in Table 2.

**Table 2.** Variants of concern (VOC) and variants of interest (VOI), according to WHO classifications as of 11 May 2021.

<table>
<thead>
<tr>
<th>SARS-CoV-2 Variants WHO classification</th>
<th>Lineage</th>
<th>First detected by</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variant of concern</td>
<td>B.1.1.7</td>
<td>United Kingdom</td>
</tr>
<tr>
<td></td>
<td>B.1.351</td>
<td>South Africa</td>
</tr>
<tr>
<td></td>
<td>P.1</td>
<td>Brazil / Japan</td>
</tr>
<tr>
<td></td>
<td>B.1.617</td>
<td>India</td>
</tr>
<tr>
<td>Variant of interest</td>
<td>B.1.525</td>
<td>United Kingdom / Nigeria</td>
</tr>
<tr>
<td></td>
<td>B.1.427/B.1.429</td>
<td>United States of America</td>
</tr>
<tr>
<td></td>
<td>B.1.1.28.2, alias P.2</td>
<td>Brazil</td>
</tr>
<tr>
<td></td>
<td>B.1.1.28.3, alias P.3</td>
<td>Philippines and Japan</td>
</tr>
<tr>
<td></td>
<td>B.1.526 with E484K or S477N</td>
<td>United States of America</td>
</tr>
<tr>
<td></td>
<td>B.1.616</td>
<td>France</td>
</tr>
</tbody>
</table>

**Note:** The B.1.617 lineage is divided into three sublineages (B.1.617.1, B.1.617.2 and B.1.617.3), which differ in mutations and phenotypic characteristics. The currently available data is too limited to make clear distinctions between sublineages currently.

**Source:** WHO. COVID-19 Weekly Epidemiological Update. Published on 11 May 2021.\(^\text{15}\)

Globally, an increase in the number of countries and territories reporting VOC and VOI continues to be observed. However, this increase must take into account the limitations related to surveillance systems or surveillance mechanisms, as well as the capacity of the countries and territories to sequence samples and differences in the selection of samples to be sequenced.

\(^{14}\) WHO. Weekly Epidemiological Update on COVID-19. 11 May 2021. Available at: https://bit.ly/3v6e0Mi

Pan American Health Organization • http://www.paho.org • © PAHO/WHO, 2021
Table 3. Summary of the countries/territories reporting cases of variants of concern (VOC), as of 17 May 2021.

<table>
<thead>
<tr>
<th>Summary</th>
<th>Name of the variant *</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>B.1.1.7</td>
</tr>
<tr>
<td>Number of countries/territories</td>
<td>142</td>
</tr>
<tr>
<td>reporting cases globally*</td>
<td></td>
</tr>
<tr>
<td>Number of countries/territories</td>
<td>36</td>
</tr>
<tr>
<td>reporting cases in the Americas</td>
<td></td>
</tr>
</tbody>
</table>

Note:
*Global data correspond to the WHO COVID-19 Weekly Epidemiological Update. Published on 11 May 2021. Some countries/territories have reported more than one variant of concern (VOC).

Source: WHO. COVID-19 Weekly Epidemiological Update. Published on 11 May 2021. Information shared by the International Health Regulations (IHR) National Focal Points (NFPs) or published on the websites of the Ministries of Health, Health Agencies, or similar, and reproduced by PAHO/WHO.

Regarding the situation in the Americas, as of 17 May 2021, 39 countries/territories have reported the detection of cases of VOC, representing 3 additional countries (Bolivia, Dominica, and Haiti) since the 14 April 2021 PAHO/WHO COVID-19 Epidemiological Update. As of 17 May 2021, the detection of the four VOC has been reported in Argentina, Aruba, Canada, Mexico, Panama, and the United States of America. Additionally, Brazil, Chile, Costa Rica, French Guiana, Puerto Rico, and Suriname have detected three VOC. (Table 3)
Table 4. Countries and territories reporting variants of concern (VOC) in the Region of the Americas, as of 17 May 2021.

<table>
<thead>
<tr>
<th>Country</th>
<th>B.1.1.7</th>
<th>B.1.351</th>
<th>P.1</th>
<th>B.1.617</th>
</tr>
</thead>
<tbody>
<tr>
<td>Argentina</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Aruba</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Barbados</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Belize</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Bolivia</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Bonaire</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Brazil</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Canada</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Cayman Islands</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Chile</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Colombia</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Cuba</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Curacao</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Dominican Republic</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Ecuador</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>French Guiana</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Grenada</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Guadeloupe</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Guyana</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Haiti</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Jamaica</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Martinique</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Mexico</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Panama</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Paraguay</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Peru</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Saint Barthélemy</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Saint Lucia</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Saint Martin</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Sint Maarten</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Suriname</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Trinidad and Tobago</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Turks and Caicos</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>United States of America</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Uruguay</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Venezuela</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Note: Data are provisional and subject to change as countries and territories make adjustments and retrospective analysis.

Source: Information shared by the IHR National Focal Points (NFPs) or published on the websites of the Ministries of Health, Health Agencies or similar, and reproduced by PAHO/WHO.


Pan American Health Organization • http://www.paho.org • © PAHO/WHO, 2021
II. COVID-19 among older adults (≥60 years of age)

Some of the articles published\cite{15,16,17}, or pre-published, on the impact of COVID-19 vaccination campaigns provide hope in achieving a decrease in mortality rates and hospitalizations in intensive care units (ICU) among older adults (≥60 years of age). However, it is important to consider that COVID-19 vaccination campaigns are not sufficient by themselves to prevent the transmission of SARS-CoV-2; therefore, public health and social distancing measures should be maintained in accordance with the epidemiological situation of each country and territory.

The trend that has been observed since the beginning of the pandemic, in relation to mortality rates among older adults, has also observed in Cuba. At the national level, persons aged ≥60 years had mortality rates ranging from 0.12 deaths per 100,000 population (in June 2020) to 6.63 deaths per 100,000 population (in April 2021). In comparison, persons aged ≤59 years of age had mortality rates ranging from 0.00 deaths per 100,000 population (in June and July 2020) to 0.74 deaths per 100,000 population (April 2021) (Figure 4). Older adults account for 80% of all COVID-19 deaths reported nationally.

Of note, as has been observed in other countries in the Americas, there has been a significant change in mortality rates among the group of ≤59 years of age. When comparing the December 2020 age-specific mortality rates with those of April 2021, there was an increase from 0.02 to 0.74 deaths per 100,000 population among persons aged ≤59 years, while the older adults increased from 0.33 to 6.63 deaths per 100,000 population.

**Figure 4.** Monthly age-specific mortality rates of COVID-19 among older adults (≥60 years) and persons aged 59 years and younger. Cuba. March 2020 to April 2021.

Note: *Rates per 100,000 population.

Source: Data published by COVID19CubaData and analyzed by PAHO/WHO.

\cite{15} Cook TM, Roberts JV. Impact of vaccination by priority group on UK deaths, hospital admissions and intensive care admissions from COVID-19. Available at: https://doi.org/10.1111/anae.15442
\cite{17} Haas E, Angulo F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet, 2021, ISSN 0140-6736. Available at: https://doi.org/10.1016/S0140-6736(21)00947-8
When disaggregating the mortality rates of the elderly into three age subgroups and analyzing the trend between March 2020 and April 2021, it is observed that, the older the age, the higher the mortality rate is for both sexes.

Across the three age subgroups, an increase in rates was observed from January 2021; in fact, during January-April 2021, the highest rates since the notification of the first confirmed cases in March 2020 were observed (Figure 5).

**Figure 5.** Age-specific mortality rates of COVID-19 among older adults (≥60 years), by month and sex. Cuba. March 2020 to April 2021.

![Age-specific mortality rates of COVID-19 among older adults (≥60 years), by month and sex. Cuba. March 2020 to April 2021.](image)

*Note:* *Rate per 100,000 population among persons ≥60 years of age.*

*Source:* Data published by COVID19CubaData and analyzed by PAHO/WHO.

**III. COVID-19 during pregnancy**

Although researchers continue to advance the knowledge base related to COVID-19 among pregnant women, helping to close existing knowledge gaps related to the impact of SARS-CoV-2 infection on the final outcome of pregnancy; accordingly, it is necessary to continue collecting information to contribute to that knowledge base.
Compared to the data reported in 2020, an increase in both the number of cases and deaths among pregnant women positive to SARS-CoV-2 has been reported in the 12 countries\(^{18}\) listed in Table 5. An increase has been observed from January through April 2021 and, if the increasing trend continues, the number of cases and deaths reported this year will soon exceed the numbers reported for all of 2020.

COVID-19 vaccination campaigns, together with social distancing measures, hand hygiene and the proper use of face masks, targeted to this population group are expected to impact the severity and mortality observed thus far.

**Table 5.** Select COVID-19 indicators during pregnancy in countries of the Americas. 2020 and 2021 (January to April).

<table>
<thead>
<tr>
<th>Country</th>
<th>Number of pregnant women positive for SARS-CoV-2</th>
<th>Number of deaths among pregnant women positive for SARS-CoV-2</th>
<th>MMR*</th>
<th>Number of pregnant women positive for SARS-CoV-2</th>
<th>Number of deaths among pregnant women positive for SARS-CoV-2</th>
<th>MMR*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Argentina</td>
<td>8,592</td>
<td>40</td>
<td>5.3</td>
<td>3,511</td>
<td>16</td>
<td>2.1</td>
</tr>
<tr>
<td>Chile</td>
<td>8,976</td>
<td>5</td>
<td>2.2</td>
<td>5,779</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Colombia</td>
<td>7,626</td>
<td>56</td>
<td>8.0</td>
<td>2,369</td>
<td>13</td>
<td>1.5</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>335</td>
<td>3</td>
<td>5.1</td>
<td>210</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Cuba</td>
<td>95</td>
<td>0</td>
<td>0.0</td>
<td>619</td>
<td>1</td>
<td>0.9</td>
</tr>
<tr>
<td>Guatemala</td>
<td>653</td>
<td>8</td>
<td>1.9</td>
<td>294</td>
<td>1</td>
<td>0.2</td>
</tr>
<tr>
<td>México&amp;</td>
<td>10,530</td>
<td>205</td>
<td>10.1</td>
<td>5,438</td>
<td>133</td>
<td>20.9</td>
</tr>
<tr>
<td>Panamá&amp;</td>
<td>1,852</td>
<td>4</td>
<td>5.0</td>
<td>561</td>
<td>3</td>
<td>3.8</td>
</tr>
<tr>
<td>Paraguay</td>
<td>599</td>
<td>1</td>
<td>0.7</td>
<td>631</td>
<td>14</td>
<td>9.8</td>
</tr>
<tr>
<td>Saint Lucia</td>
<td>2</td>
<td>0</td>
<td>0.0</td>
<td>13</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Suriname</td>
<td>41</td>
<td>0</td>
<td>0.0</td>
<td>36</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Uruguay</td>
<td>82</td>
<td>0</td>
<td>0.0</td>
<td>742</td>
<td>1</td>
<td>2.1</td>
</tr>
</tbody>
</table>

**Note:** \(^{18}\) Corresponds to pregnant and postpartum women

* MMR Maternal mortality ratio, calculated using deaths among pregnant women (in some instances, including postpartum deaths) positive to SARS-CoV-2

**Source:** Latin American Center for Perinatology/Women’s Health and Reproductive Health (CLAP/SMR) and information shared with PAHO/WHO by IHR National Focal Points (NFPs) or published on the websites of the Ministries of Health, health agencies, or similar and reproduced by PAHO/WHO.

Since the first reported cases of COVID-19 in the Americas and until 17 May 2021, there have been a total of 202,101 SARS-CoV-2 infections among pregnant women, including 1,271 deaths (0.63% case-fatality rate), reported in 24 countries/territories for which information was available.

Compared to the data presented in the 14 April 2021 PAHO/WHO COVID-19 Epidemiological Update\(^4\), this represents 10,201 additional cases and 169 additional deaths. During the same period, the highest relative increases in cumulative confirmed cases occurred in the Dominican Republic and Uruguay, while for deaths, the highest relative increase was observed in Paraguay (Table 6).

<table>
<thead>
<tr>
<th>Country</th>
<th>Number of pregnant women positive for SARS-CoV-2</th>
<th>Number of deaths among pregnant women positive for SARS-CoV-2</th>
<th>Case fatality rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Argentina</td>
<td>12,103</td>
<td>56</td>
<td>0.46</td>
</tr>
<tr>
<td>Bahamas</td>
<td>42</td>
<td>1</td>
<td>2.38</td>
</tr>
<tr>
<td>Bolivia</td>
<td>1,858</td>
<td>31</td>
<td>1.67</td>
</tr>
<tr>
<td>Belize</td>
<td>228</td>
<td>2</td>
<td>0.88</td>
</tr>
<tr>
<td>Brazil</td>
<td>5,931</td>
<td>428</td>
<td>7.22</td>
</tr>
<tr>
<td>Chile</td>
<td>9,764</td>
<td>5</td>
<td>0.05</td>
</tr>
<tr>
<td>Colombia</td>
<td>9,995</td>
<td>69</td>
<td>0.69</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>545</td>
<td>3</td>
<td>0.55</td>
</tr>
<tr>
<td>Cuba</td>
<td>714</td>
<td>1</td>
<td>0.14</td>
</tr>
<tr>
<td>Dominican Republic</td>
<td>955</td>
<td>42</td>
<td>4.40</td>
</tr>
<tr>
<td>Ecuador</td>
<td>2,145</td>
<td>29</td>
<td>1.35</td>
</tr>
<tr>
<td>El Salvador**</td>
<td>272</td>
<td>9</td>
<td>3.31</td>
</tr>
<tr>
<td>Guatemala</td>
<td>947</td>
<td>9</td>
<td>0.95</td>
</tr>
<tr>
<td>Haiti</td>
<td>82</td>
<td>4</td>
<td>4.88</td>
</tr>
<tr>
<td>Honduras</td>
<td>36</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Mexico&amp;</td>
<td>16,132</td>
<td>334</td>
<td>2.07</td>
</tr>
<tr>
<td>Panama&amp;</td>
<td>2,413</td>
<td>12</td>
<td>0.50</td>
</tr>
<tr>
<td>Paraguay</td>
<td>1,230</td>
<td>15</td>
<td>1.22</td>
</tr>
<tr>
<td>Peru**</td>
<td>46,524</td>
<td>114</td>
<td>0.25</td>
</tr>
<tr>
<td>Saint Lucia</td>
<td>15</td>
<td>0</td>
<td>0.00</td>
</tr>
<tr>
<td>Suriname</td>
<td>77</td>
<td>0</td>
<td>0.00</td>
</tr>
<tr>
<td>United States of America</td>
<td>88,880</td>
<td>99</td>
<td>0.11</td>
</tr>
<tr>
<td>Uruguay</td>
<td>824</td>
<td>1</td>
<td>0.12</td>
</tr>
<tr>
<td>Venezuela**</td>
<td>389</td>
<td>7</td>
<td>1.80</td>
</tr>
<tr>
<td>**Total</td>
<td>202,101</td>
<td>1,271</td>
<td>0.63</td>
</tr>
</tbody>
</table>

Note: N/A: Data not available.
*17 May 2021 corresponds to the date of the most recent report received by PAHO/WHO; there may be differences in the dates that each country provided the last report to PAHO/WHO or published the report. Preliminary data subject to change based on retrospective investigation.
** No update since the 14 April 2021 PAHO/WHO Epidemiological Update on COVID-19³
&a Corresponds to pregnant and postpartum women

Source: Latin American Center for Perinatology/Women’s Health and Reproductive Health (CLAP/SMR) and information shared with PAHO/WHO by IHR National Focal Points (NFPs) or published on the websites of the Ministries of Health, health agencies, or similar and reproduced by PAHO/WHO.

IV. COVID-19 among indigenous populations

Since January 2020 until 17 May 2021, there have been 448,956 confirmed cases of COVID-19, including 7,884 deaths, reported among indigenous populations in 18 countries in the Region of the Americas for which information was available (Table 7). Compared to the data in the 14 April 2021 PAHO/WHO Epidemiological Update on COVID-19⁴, this represents 25,533 additional confirmed cases including 914 deaths.

In comparison with previous PAHO/WHO Epidemiological Update, the highest increase in both cases and deaths was observed in Paraguay.
Table 7. Cumulative number of confirmed cases and deaths of COVID-19 among indigenous populations in the Region of the Americas. January 2020 to 17 May 2021*.

<table>
<thead>
<tr>
<th>Country</th>
<th>Number of COVID-19 confirmed cases</th>
<th>Number of deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Argentina</td>
<td>1,504</td>
<td>45</td>
</tr>
<tr>
<td>Belize</td>
<td>1,668</td>
<td>41</td>
</tr>
<tr>
<td>Bolivia</td>
<td>13,118</td>
<td>295</td>
</tr>
<tr>
<td>Brazil</td>
<td>48,036</td>
<td>672</td>
</tr>
<tr>
<td>Canada</td>
<td>28,118</td>
<td>326</td>
</tr>
<tr>
<td>Chile**</td>
<td>40,745</td>
<td>703</td>
</tr>
<tr>
<td>Colombia</td>
<td>46,772</td>
<td>1,425</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>158</td>
<td>33</td>
</tr>
<tr>
<td>Ecuador**</td>
<td>5,153</td>
<td>206</td>
</tr>
<tr>
<td>Guatemala</td>
<td>13,575</td>
<td>488</td>
</tr>
<tr>
<td>Guyana**</td>
<td>95</td>
<td>6</td>
</tr>
<tr>
<td>Mexico</td>
<td>19,149</td>
<td>2,904</td>
</tr>
<tr>
<td>Panama**</td>
<td>5,807</td>
<td>102</td>
</tr>
<tr>
<td>Paraguay</td>
<td>376</td>
<td>38</td>
</tr>
<tr>
<td>Peru</td>
<td>27,838</td>
<td>540</td>
</tr>
<tr>
<td>Suriname</td>
<td>604</td>
<td>32</td>
</tr>
<tr>
<td>United States of America</td>
<td>195,379</td>
<td>N/A</td>
</tr>
<tr>
<td>Venezuela**</td>
<td>861</td>
<td>28</td>
</tr>
<tr>
<td>**Total</td>
<td>448,956</td>
<td>7,884</td>
</tr>
</tbody>
</table>

Note: N/A: data not available
*17 May 2021 corresponds to the date of the most recent report received by PAHO/WHO; there may be differences in the dates that each country provided the last report to PAHO/WHO or published the report. Preliminary data subject to change based on retrospective investigation.
** No update since the 14 April 2021 PAHO/WHO Epidemiological Update on COVID-19.

Source: Data provided by the International Health Regulations (IHR) National Focal Points (NFPs) or published by the Ministries of Health, Institutes of Health, indigenous organizations, or similar and reproduced by PAHO/WHO.

Following is a description of the COVID-19 epidemiological situation among indigenous populations of Canada.

In Canada, since the confirmation of the first case until 11 May 2021, there were 28,118 confirmed COVID-19 cases among indigenous populations, including 326 deaths. Of the total confirmed cases, 26,972 are reported as recovered (96%). The provinces of Alberta (8,103 cases), Manitoba (7,518 cases), and Saskatchewan (6,742 cases) account for 80% of all confirmed cases among indigenous populations in Canada.

In Canada, indigenous populations are part of the priority groups for COVID-19 vaccination. Mass vaccination campaigns in indigenous communities began the week of 17 January 2021, a date that coincides with the start of the decline in active cases reported. When looking at Figure...
6. an inverse relationship is observed between the number of cumulative active cases and the number of vaccine doses administered.

As of 12 May 2021, a total of 416,106 doses have been administered, of which 134,740 were second doses, among this population group.

Figure 6. Number of active COVID-19 cases among the First Nations communities by report week and number of COVID-19 vaccine doses administered, Canada. As of 11 May 2021.

Note: *Cumulative total of COVID-19 doses administered, including first and second doses.


V. COVID-19 among populations under 20 years of age

Since the beginning of the pandemic, it has been apparent that children and adolescents have a lower risk of illness and death from COVID-19 compared to other age groups. As well, it has been recognized that children and adolescents are being affected mainly by the measures taken to control the transmission of the virus. These indirect effects include the negative consequences of school closures, restrictions on the movement of people which limit opportunities for play and relationships with family and friends, the loss of work and income that also affect the mental health of caregivers and consequently the relationships between children and their caregivers, and the alteration of health and social protection service functions, among others. The number of studies documenting the magnitude of these effects on the health, development, and learning of children and adolescents, is growing.

---


The evidence available thus far suggests that children and adolescents are less susceptible to SARS-CoV-2 infection and also transmit the virus less frequently than adults. When they acquire infection, they are generally asymptomatic and, when they do get sick, they usually have mild illness with symptoms similar to other common illnesses in these ages. Within the 0-19 age group, studies suggest that susceptibility and transmission are lower among children under 5 years of age than among older children and adolescents.21,22,23,24,25

The following is an analysis of the age-specific incidence rates among children and adolescents between March and December 2020 in Cuba, per the available data.

In Figure 7, 15-19-year-olds reflect a higher incidence rate of becoming ill, among both males and females; additionally, two important increases are observed for each of the sexes: the first in April among both sexes and a second in October among males and in August-September among females.

Figure 7. Age-specific COVID-19 incidence rates among children and adolescents, by sex. Cuba. March to December 2020.

---

Note: *Rate per 100,000 population among persons aged < 20 years.

Source: Data published by COVID19CubaData and analyzed by PAHO/WHO. For the first time since the first cases were reported in the country, an increase has been observed between January and May 2021 not only in incidence rates, but also in serious and critical conditions being reported among cases in population group under 20 years of age.

Between March 2020 and 11 May 2021, 17.5% of the total cases nationally correspond to the under 20 years of age group (20,891), of which 15,246 are under 18 years of age and among these, 812 are under 1 year of age. Overall, 97% of cases among children under 20 years of age have been reported in 2021.

When considering the epidemiological situation between 26 April and 10 May 2021, an average of 152 cases per day was reported among children under 18 years of age. In this same period, the age-specific incidence rates ranged from 4.1 to 8.5 cases per 100,000 population among children under 20 years of age (Figure 8).

Figure 8. Number of cases and age-specific incidence rates for COVID-19 among children aged < 20 years, by confirmation date. Cuba. 23 April to 10 May 2021.

Multisystem inflammatory syndrome in children and adolescents (MIS-C) temporally related to COVID-19

Various reports and scientific publications, from different places worldwide, have described groups of children and adolescents requiring admission to intensive care units (ICU) with a multisystem inflammatory condition with some features similar to those of Kawasaki disease and toxic shock syndrome. Based on the available evidence, WHO has provided the case definition

---


Although MIS-C occurs relatively infrequently, these cases present important challenges for health systems.

In the Region of the Americas, since June 2020, PAHO/WHO began active surveillance of MIS-C cases, inviting Member States to share minimum epidemiological surveillance variables allowing for the characterization of MIS-C in the Region.

Between mid-May 2020 and 17 May 2021, a cumulative total of 5,555 confirmed cases of MIS-C temporally related to COVID-19, including 123 deaths, have been reported in 22 countries/territories of the Region of the Americas (Table 8).

Since the 14 April 2021 PAHO/WHO Epidemiological Update on COVID-19 to 17 May 2021, an additional 595 confirmed cases were reported, including 12 deaths. During this same period, 23 countries and territories have officially reported to PAHO/WHO that they have not detected cases of MIS-C.

As the numbers of cases of MIS-C increase, it is important that each country/territory characterizes the cases27 in order to contribute to closing the gaps in information, particularly related to clinical management and response measures.

---

27 WHO. Case Report Form for suspected cases of multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19. Available at: https://bit.ly/3cTmrUF
Table 8. Distribution of cumulative confirmed cases and deaths of multisystem inflammatory syndrome in children and adolescents (MIS-C) temporally related to COVID-19 in the Region of the Americas, by country/territory. May 2020 to 17 May 2021.*

<table>
<thead>
<tr>
<th>Country/Territory</th>
<th>Number of confirmed cases</th>
<th>Number of confirmed deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Argentina</td>
<td>128</td>
<td>1</td>
</tr>
<tr>
<td>Barbados</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Brazil</td>
<td>952</td>
<td>63</td>
</tr>
<tr>
<td>Bolivia</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Canada</td>
<td>94</td>
<td>0</td>
</tr>
<tr>
<td>Chile</td>
<td>286</td>
<td>5</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>33</td>
<td>0</td>
</tr>
<tr>
<td>Colombia</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>Cuba</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Dominican Republic</td>
<td>132</td>
<td>6</td>
</tr>
<tr>
<td>Ecuador</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>El Salvador</td>
<td>19</td>
<td>0</td>
</tr>
<tr>
<td>French Guiana</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Guadeloupe</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Guatemala</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Honduras</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Panama</td>
<td>81</td>
<td>2</td>
</tr>
<tr>
<td>Paraguay</td>
<td>79</td>
<td>6</td>
</tr>
<tr>
<td>Peru</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Saint Martin</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Trinidad and Tobago</td>
<td>29</td>
<td>0</td>
</tr>
<tr>
<td>United States of America</td>
<td>3,685</td>
<td>35</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>5,555</strong></td>
<td><strong>123</strong></td>
</tr>
</tbody>
</table>

Note: *17 May 2021 corresponds to the date of the most recent report received by PAHO/WHO; there may be differences in the dates that each country provided the last report to PAHO/WHO or published the report. Preliminary data subject to change based on retrospective investigation.

Sources: Data provided by the International Health Regulations National Focal Points or published by the Ministries of Health, Institutes of Health, or similar health agencies and reproduced by PAHO/WHO.

The following is a brief description of the epidemiological situation of MIS-C in the Americas.

As of 17 May 2021, Cuba has reported 4 MIS-C cases and no deaths.

Of the total number of reported cases for which data on age and sex were available (n=4,851), 30% were aged 0 to 4 years, 34% aged 5 to 9 years, 26% aged 10 to 14 years, and 11% aged 15 to 19 years (the United States of America includes 20-year-olds in this age group). Regarding the distribution by sex, 59% of the cases were male.

Among 120 fatal cases for which data on age and sex were available, 40% were aged 0 to 4 years, 20% aged 5 to 9 years, 15% aged 10 to 14 years, and 25% aged 15 to 19 years, and 51% were male.
VI. COVID-19 among health workers

Since the first confirmed cases of COVID-19 were reported and until 12 May 2021, there were 1,827,427 COVID-19 cases among health care workers, including 9,161 deaths, per the data made available by 23 countries in the Americas (Table 9). This represents 12% of the estimated 15 million health workers in the Americas.28


<table>
<thead>
<tr>
<th>Country</th>
<th>Number of confirmed cases of COVID-19</th>
<th>Number of deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Argentina</td>
<td>84,493</td>
<td>496</td>
</tr>
<tr>
<td>Bahamas</td>
<td>505</td>
<td>13</td>
</tr>
<tr>
<td>Belice</td>
<td>315</td>
<td>2</td>
</tr>
<tr>
<td>Bolivia</td>
<td>21,659</td>
<td>430</td>
</tr>
<tr>
<td>Brazil</td>
<td>753,089</td>
<td>656</td>
</tr>
<tr>
<td>Chile</td>
<td>66,606</td>
<td>102</td>
</tr>
<tr>
<td>Colombia</td>
<td>57,321</td>
<td>274</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>7,717</td>
<td>33</td>
</tr>
<tr>
<td>Ecuador</td>
<td>12,306</td>
<td>118</td>
</tr>
<tr>
<td>El Salvador**</td>
<td>6,609</td>
<td>72</td>
</tr>
<tr>
<td>Dominican Republic</td>
<td>972</td>
<td>21</td>
</tr>
<tr>
<td>Guatemala</td>
<td>6,438</td>
<td>60</td>
</tr>
<tr>
<td>Haiti</td>
<td>808</td>
<td>1</td>
</tr>
<tr>
<td>Jamaica</td>
<td>861</td>
<td>4</td>
</tr>
<tr>
<td>Mexico£</td>
<td>235,961</td>
<td>3,861</td>
</tr>
<tr>
<td>Panama**</td>
<td>7,925</td>
<td>123</td>
</tr>
<tr>
<td>Paraguay</td>
<td>12,857</td>
<td>132</td>
</tr>
<tr>
<td>Peru</td>
<td>57,901</td>
<td>1,001</td>
</tr>
<tr>
<td>Saint Lucia</td>
<td>133</td>
<td>0</td>
</tr>
<tr>
<td>Suriname</td>
<td>450</td>
<td>0</td>
</tr>
<tr>
<td>United States of America</td>
<td>482,432</td>
<td>1,579</td>
</tr>
<tr>
<td>Uruguay</td>
<td>7,043</td>
<td>18</td>
</tr>
<tr>
<td>Venezuela</td>
<td>3,026</td>
<td>165</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>1,827,427</strong></td>
<td><strong>9,161</strong></td>
</tr>
</tbody>
</table>

Note:
*17 May 2021 corresponds to the date of the most recent report received by PAHO/WHO; there may be differences in the dates that each country provided the last report to PAHO/WHO or published the report. Preliminary data subject to change based on retrospective investigation.
** No update since the 14 April 2021 PAHO/WHO Epidemiological Update on COVID-19.19
£ The information that Mexico presents corresponds to the occupation variable of the Epidemiological Surveillance System for Viral Respiratory Disease (SISVER). The analysis reflects the cases that reported performing a health-related occupation. It is important to clarify that the information collected in SISVER does not allow to identify if the contagion occurred in the workplace, at home or in the community; nor does it establish whether health personnel are currently working in a medical care unit.

Source: Data provided by the IHR National Focal Points (NFPs) or published by the Ministries of Health, Institutes of Health, or similar health agencies and reproduced by PAHO/WHO.

Guidance for national authorities

PAHO/WHO continues to reiterate and update recommendations to support all Member States on management and protection measures for COVID-19 and reiterates the recommendations included in the PAHO/WHO Epidemiological Alerts and Updates on COVID-19 available at: https://www.paho.org/en/epidemiological-alerts-and-updates.

The following are guidance, scientific reports, and other resources published by PAHO/WHO and WHO.

<table>
<thead>
<tr>
<th>Surveillance, rapid response teams, and case investigation</th>
<th>Clinical management</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Laboratory</th>
<th>Infection prevention and control</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Critical preparedness and response</th>
<th>Travel, Points of entry, and border health</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Schools, workplaces, &amp; other institutions</th>
<th>Other resources</th>
</tr>
</thead>
</table>
References


2. WHO. COVID-19 Weekly Epidemiological Update. Published on 11 May 2021. Available at: https://bit.ly/3v6e0Mi

3. Report by the Argentina International Health Regulations (IHR) National Focal Point (NFP), received by PAHO/WHO via email

4. Report by the Bolivia International Health Regulations (IHR) National Focal Point (NFP), received by PAHO/WHO via email


7. Report by the Chile International Health Regulations (IHR) National Focal Point (NFP), received by PAHO/WHO via email

8. Report by the Colombia International Health Regulations (IHR) National Focal Point (NFP), received by PAHO/WHO via email

9. Report by the Costa Rica International Health Regulations (IHR) National Focal Point (NFP), received by PAHO/WHO via email


12. Report by the Dominican Republic International Health Regulations (IHR) National Focal Point (NFP), received by PAHO/WHO via email

13. Report by the Ecuador International Health Regulations (IHR) National Focal Point (NFP), received by PAHO/WHO via email

14. Report by the Mexico International Health Regulations (IHR) National Focal Point (NFP), received by PAHO/WHO via email

15. Report by the Paraguay International Health Regulations (IHR) National Focal Point (NFP), received by PAHO/WHO via email

16. Report by the Saint Lucia International Health Regulations (IHR) National Focal Point (NFP), received by PAHO/WHO via email

- 23 -

17. Report by the **Suriname** International Health Regulations (IHR) National Focal Point (NFP), received by PAHO/WHO via email


19. Report by the **Uruguay** International Health Regulations (IHR) National Focal Point (NFP), received by PAHO/WHO via email